Capricor Therapeutics Inc (CAPR.OQ)
CAPR.OQ on NASDAQ Stock Exchange Capital Market
1.33USD
9:00pm BST
1.33USD
9:00pm BST
Change (% chg)
$-0.01 (-0.75%)
$-0.01 (-0.75%)
Prev Close
$1.34
$1.34
Open
$1.33
$1.33
Day's High
$1.38
$1.38
Day's Low
$1.32
$1.32
Volume
28,269
28,269
Avg. Vol
68,185
68,185
52-wk High
$4.25
$4.25
52-wk Low
$0.63
$0.63
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2017 | Dec '17 | 0.48 | 0.306 |
| Sep '17 | 0.31 | -0.117 | |
| Jun '17 | 1.00 | -0.157 | |
| Mar '17 | 0.88 | -0.171 | |
| FY 2016 | Dec '16 | 0.91 | -0.211 |
| Sep '16 | 0.75 | -0.292 | |
| Jun '16 | 1.13 | -0.261 | |
| Mar '16 | 1.22 | -0.258 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 1 | 0.57 | 0.57 | 0.57 | -- |
| Quarter Ending Sep-18 | 1 | 0.90 | 0.90 | 0.90 | -- |
| Year Ending Dec-18 | 1 | 2.70 | 2.70 | 2.70 | 6.90 |
| Year Ending Dec-19 | 1 | 2.80 | 2.80 | 2.80 | 7.00 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 1 | -0.12 | -0.12 | -0.12 | -- |
| Quarter Ending Sep-18 | 1 | -0.10 | -0.10 | -0.10 | -- |
| Year Ending Dec-18 | 1 | -0.46 | -0.46 | -0.46 | -0.83 |
| Year Ending Dec-19 | 1 | -0.43 | -0.43 | -0.43 | -0.84 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | 43.20 | 173.69 | 32.21 | |
| P/E High - Last 5 Yrs. | 17.41 | 277.43 | 45.93 | |
| P/E Low - Last 5 Yrs. | 17.41 | 94.83 | 24.67 | |
| Beta | -3.19 | 0.74 | 0.79 | |
| Price to Sales (TTM) | 13.97 | 143.31 | 7.12 | |
| Price to Book (MRQ) | 3.14 | 18.56 | 4.90 | |
| Price to Tangible Book (MRQ) | 3.35 | 23.03 | 6.48 | |
| Price to Cash Flow (TTM) | 14.46 | 113.95 | 24.70 | |
| % Owned Institutions | 8.82 | 11.14 | 2.29 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 0.29 | 1.57 | |
| Dividend Yield - 5 Year Avg | -- | 0.20 | 0.77 | |
| Dividend 5 Year Growth Rate | -- | 1.99 | 4.07 | |
| Payout Ratio(TTM) | 0.00 | 9.34 | 20.78 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | -47.54 | 102.04 | 9.38 | |
| Sales (TTM) vs TTM 1 Yr. Ago | -33.32 | 78.42 | 11.18 | |
| Sales - 5 Yr. Growth Rate | 7.03 | 33.22 | 8.21 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | 245.05 | -68.08 | 24.18 | |
| EPS (TTM) vs TTM 1 Yr. Ago | 86.37 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 45.94 | 10.39 | |
| Capital Spending - 5 Yr. Growth Rate | -20.75 | 44.70 | 10.42 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | -- | 1.72 | 2.53 |
| Current Ratio (MRQ) | 9.40 | 5.98 | 3.59 |
| LT Debt to Equity (MRQ) | 30.07 | 23.74 | 11.47 |
| Total Debt to Equity (MRQ) | 30.07 | 26.24 | 14.16 |
| Interest Coverage (TTM) | -51.40 | -176.11 | 30.45 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | -- | 34.08 | 54.23 | |
| Gross Margin - 5 Yr. Avg. | -- | 55.28 | 52.19 | |
| EBITD Margin (TTM) | -476.99 | -- | -- | |
| EBITD - 5 Yr. Avg | -314.28 | -148.90 | 15.91 | |
| Operating Margin (TTM) | -482.40 | -586.11 | 3.78 | |
| Operating Margin - 5 Yr. Avg. | -336.47 | -161.04 | 11.22 | |
| Pre-Tax Margin (TTM) | 91.19 | -558.30 | 4.45 | |
| Pre-Tax Margin - 5 Yr. Avg. | -253.78 | -168.34 | 11.53 | |
| Net Profit Margin (TTM) | 91.19 | -546.50 | 1.07 | |
| Net Profit Margin - 5 Yr. Avg. | -253.78 | -168.59 | 7.86 | |
| Effective Tax Rate (TTM) | -- | -0.47 | 31.76 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 18.03 | 24.25 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | -- | 23,213,484 | 790,924,504 | |
| Net Income/Employee (TTM) | -- | 651,754 | 92,823,068 | |
| Receivable Turnover (TTM) | 9.39 | 6.13 | 5.51 | |
| Inventory Turnover (TTM) | -- | 2.42 | 3.47 | |
| Asset Turnover (TTM) | 0.15 | 0.40 | 0.88 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | 13.89 | -0.73 | 10.41 | |
| Return on Assets - 5 Yr. Avg. | -68.39 | 0.50 | 11.41 | |
| Return on Investment (TTM) | 17.09 | -0.70 | 13.05 | |
| Return on Investment - 5 Yr. Avg. | -100.87 | 4.02 | 14.78 | |
| Return on Equity (TTM) | 67.32 | -2.69 | 14.90 | |
| Return on Equity - 5 Yr. Avg. | -- | -0.12 | 16.12 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | -33.32 | -17.72 | 7.03 |
| EPS (TTM) % | 108.95 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Capricor Therapeutics Inc
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | 4.69 | 3.32 | 99 | 4 |
| 13 Week | -16.25 | -9.96 | 77 | 53 |
| 26 Week | -44.17 | -45.91 | 25 | 88 |
| 52 Week | -58.51 | -62.46 | 28 | 77 |
| YTD | -15.19 | -14.09 | 61 | 85 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- BRIEF-Capricor Q4 Earnings Per Share $0.42
- BRIEF-Capricor Therapeutics Says FDA Has Granted CAP-1002 RMAT Designation
- BRIEF-Capricor Therapeutics Appoints Anthony Bergmann As CFO, Eff Jan 1, 2018 - SEC Filing
- BRIEF-Capricor Therapeutics Announces Issuance Of Key U.S. Patent On Exosome Technology
- BRIEF-Capricor & California Institute For Regenerative Medicine Entered Into Amendment 3 To CIRM Notice Loan Award
Institutional Holders
| % Shares Owned: | 8.82% |
| # of Holders: | 25 |
| Total Shares Held: | 2,444,293 |
| 3 Mo. Net Change: | 13,264 |
| # New Positions: | 0 |
| # Closed Positions: | 0 |
| # Increased Positions: | 1 |
| # Reduced Positions: | 0 |
| # Net Buyers: | 1 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.